Prognostic molecular biomarkers for cutaneous malignant melanoma

Authors

  • Ryo Tanaka MD, PhD,

    1. Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California
    Search for more papers by this author
  • Kazuo Koyanagi MD, PhD,

    1. Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California
    Search for more papers by this author
  • Norihiko Narita MD, PhD,

    1. Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California
    Search for more papers by this author
  • Christine Kuo PsyD,

    1. Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California
    Search for more papers by this author
  • Dave S.B. Hoon PhD

    Corresponding author
    1. Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California
    • Dept of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404. Fax: 310-449-5282.===

    Search for more papers by this author

  • All authors disclose no financial/commercial conflict of interest except that Dr. D. Hoon has licensing agreement with Abraxis Healthcare on several of the biomarkers discussed in this manuscript.

Abstract

Molecular signatures of melanoma have propelled new approaches to early diagnosis, monitoring of treatment response, and targeted therapy. This review discusses messenger RNA (mRNA), genomic, and epigenomic melanoma biomarkers in blood and tissue specimens. The major focus is on tissue-based molecular assays to upstage sentinel lymph nodes (SLNs), and blood-based assays to detect melanoma progression by monitoring levels of circulating tumor cells (CTC) and circulating DNA. J. Surg. Oncol. 2011; 104:438–446. © 2011 Wiley-Liss, Inc.

Ancillary